person · Reporting owner
LAPOINTE ANTHONY GREGG
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CTYX · Entity 7637 | Director | May 22, 2017 | May 24, 2017 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
| SOLIGENIX, INC.SNGX · Entity 8067 | Director | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date May 22, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2027-03-31 | Direct | 50,000 |
Reported balance
After 2017-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-22 · Grant · Acquired 50,000 · Balance 50,000 F1: The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the "Restated Plan") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017. F2: Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the "Restated Plan") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017.
F2: Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,250 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 18,250 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
SOLIGENIX, INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $549.60 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-12 · Disposition to issuer · Disposed 54 · Balance 0 F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $400.80 · Expires 2028-09-26 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-12 · Disposition to issuer · Disposed 74 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $232.80 · Expires 2029-09-05 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-12 · Disposition to issuer · Disposed 128 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $472.80 · Expires 2030-09-15 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-12 · Disposition to issuer · Disposed 63 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $247.20 · Expires 2031-09-22 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Disposition to issuer · Disposed 121 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.00 · Expires 2032-11-16 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-12 · Disposition to issuer · Disposed 192 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Astria Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Disposition to issuer · Disposed 16,666 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Disposition to issuer · Disposed 8,333 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-23 · Disposition to issuer · Disposed 26,550 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-10-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-24 · Other · Disposed 2,092 · Balance 8,330 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 8,330 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 7,915 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
SCICLONE PHARMACEUTICALS INC
Report date October 13, 2017 · Filed October 16, 2017
Section 16 reporting ended · disclosed 2017-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2019-03-30 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-13 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F1: Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of service as an outside director of the Issuer, beginning March 30, 2010, and became immediately exercisable and vested in full as of March 30, 2012. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2019-06-09 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-13 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2020-06-10 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2022-06-07 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2023-06-27 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2025-06-11 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of service as an outside director of the Issuer, beginning March 30, 2010, and became immediately exercisable and vested in full as of March 30, 2012.
F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010.
F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011.
F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2017 Filed Oct 16, 2017 17:11 UTC | SCICLONE PHARMACEUTICALS INC SCLN · Entity 172474 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $5.14 Strike: $6.04 | $154,200.00 |
DisclosureSEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 4 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-06-30 F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F5 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 17:11 UTC | SCICLONE PHARMACEUTICALS INC SCLN · Entity 172474 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $8.17 Strike: $3.01 | $245,100.00 |
DisclosureSEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 3 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-06-10 F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F4 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 17:11 UTC | SCICLONE PHARMACEUTICALS INC SCLN · Entity 172474 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $8.95 Strike: $2.23 | $44,750.00 |
DisclosureSEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 2 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-06-09 F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F3 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 17:11 UTC | SCICLONE PHARMACEUTICALS INC SCLN · Entity 172474 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $9.94 Strike: $1.24 | $497,000.00 |
DisclosureSEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-03-30 F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F1 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of service as an outside director of the Issuer, beginning March 30, 2010, and became immediately exercisable and vested in full as of March 30, 2012. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 16:23 UTC | SCICLONE PHARMACEUTICALS INC SCLN · Entity 172474 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0000880771-17-000097 · certent-form4.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director · Board Member 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-08 F1 · security: Granted under the Issuer's 2015 Equity Incentive Plan. F2 · derivative.exercise_date: Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006381 · f4060817lapointe_soligenix.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:35 UTC | CERENOME, INC. CTYX · Entity 7637 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-17-034968 · doc4.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-03-31 F1 · derivative.exercise_price: The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the "Restated Plan") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017. F2 · derivative.exercise_date: Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:39 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerStock Option (right to buy) · Derivative | 7,915 | Not disclosed Strike: $5.22 | Not disclosed |
DisclosureSEC source: 0001140361-16-083649 · doc1.xml · derivative · entry 3 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,915 shares Expires 2026-04-15 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:39 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerCommon Stock | 8,330 | $9.00 | $74,970.00 |
DisclosureSEC source: 0001140361-16-083649 · doc1.xml · nonDerivative · entry 2 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 16:39 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | OtherCommon Stock | 2,092 | $9.00 | $18,828.00 |
DisclosureSEC source: 0001140361-16-083649 · doc1.xml · nonDerivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,330 F1 · kind: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.